Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Prostate Cancer

  Free Subscription


17.08.2020

2 BMC Cancer
1 Br J Radiol
1 Cancer
1 Cancer Imaging
1 Cancer Lett
1 Eur Radiol
1 Eur Urol
2 Int J Urol
1 J Magn Reson Imaging
1 J Nucl Med
3 J Urol
1 Oncogene
2 Oncology (Williston Park)
4 PLoS One
4 Prostate
2 Urol Int
2 Urology


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    BMC Cancer

  1. HOUEDE N, Rebillard X, Bouvet S, Kabani S, et al
    Impact on quality of life 3 years after diagnosis of prostate cancer patients below 75 at diagnosis: an observational case-control study.
    BMC Cancer. 2020;20:757.
    PubMed         Abstract available

  2. CHEN J, Liu X, Ke K, Zou J, et al
    LINC00992 contributes to the oncogenic phenotypes in prostate cancer via targeting miR-3935 and augmenting GOLM1 expression.
    BMC Cancer. 2020;20:749.
    PubMed         Abstract available


    Br J Radiol

  3. SCHUMACHER LD, Dal Pra A, Hoffe SE, Mellon EA, et al
    Toxicity reduction required for MRI-guided radiotherapy to be cost-effective in the treatment of localized prostate cancer.
    Br J Radiol. 2020 Aug 12:20200028. doi: 10.1259/bjr.20200028.
    PubMed         Abstract available


    Cancer

  4. PRINTZ C
    Prostate cancer mortality projections reach a new high: With prostate cancer deaths projected to rise to their highest level in 20 years, some experts worry that changes to screening guidelines made in 2012 could be a factor.
    Cancer. 2020;126:3893-3894.
    PubMed        


    Cancer Imaging

  5. DE LEIRIS N, Leenhardt J, Boussat B, Montemagno C, et al
    Does whole-body bone SPECT/CT provide additional diagnostic information over [18F]-FCH PET/CT for the detection of bone metastases in the setting of prostate cancer biochemical recurrence?
    Cancer Imaging. 2020;20:58.
    PubMed         Abstract available


    Cancer Lett

  6. CHEN D, Chou FJ, Chen Y, Tian H, et al
    Targeting the radiation-induced TR4 nuclear receptor-mediated QKI/circZEB1/miR-141-3p/ZEB1 signaling increases prostate cancer radiosensitivity.
    Cancer Lett. 2020 Aug 5. pii: S0304-3835(20)30396.
    PubMed         Abstract available


    Eur Radiol

  7. SUN C, Wang S, Chatterjee A, Medved M, et al
    T2*-weighted MRI as a non-contrast-enhanced method for assessment of focal laser ablation zone extent in prostate cancer thermotherapy.
    Eur Radiol. 2020 Aug 12. pii: 10.1007/s00330-020-07127.
    PubMed         Abstract available


    Eur Urol

  8. SOLOWAY MS, Lokeshwar SD
    The Fallacy of "Definitive Therapy" for Prostate Cancer.
    Eur Urol. 2020 Aug 6. pii: S0302-2838(20)30545.
    PubMed         Abstract available


    Int J Urol

  9. AYDIN AM, Gage K, Dhillon J, Cheriyan SK, et al
    Focal bipolar radiofrequency ablation for localized prostate cancer: Safety and feasibility.
    Int J Urol. 2020 Aug 6. doi: 10.1111/iju.14321.
    PubMed         Abstract available

  10. KAWAHARA T
    Editorial Comment to Considerations for the use of gonadotropin-releasing hormone agonists and antagonists in patients with prostate cancer.
    Int J Urol. 2020 Aug 8. doi: 10.1111/iju.14346.
    PubMed        


    J Magn Reson Imaging

  11. CARLIN D, Orton MR, Collins D, deSouza NM, et al
    Probing structure of normal and malignant prostate tissue before and after radiation therapy with luminal water fraction and diffusion-weighted MRI.
    J Magn Reson Imaging. 2018 Dec 27. doi: 10.1002/jmri.26597.
    PubMed         Abstract available


    J Nucl Med

  12. FOSBOL MO, Kurbegovic S, Johannesen HH, Roder MA, et al
    Urokinase Plasminogen Activator Receptor (uPAR) PET/MRI of Prostate Cancer for Non-invasive Evaluation of Aggressiveness: a Prospective Phase II Clinical Trial Comparing with Gleason Score.
    J Nucl Med. 2020 Aug 6. pii: jnumed.120.248120. doi: 10.2967/jnumed.120.248120.
    PubMed         Abstract available


    J Urol

  13. SAIDIAN A, Vishwanath V, Rais-Bahrami S
    Editorial Comment.
    J Urol. 2020;203:1092-1093.
    PubMed        

  14. CARROLL PR, Chu C
    Editorial Comment.
    J Urol. 2020;203:1121.
    PubMed        

  15. O'NEIL B
    Editorial Comment.
    J Urol. 2020;203:1116.
    PubMed        


    Oncogene

  16. KO CJ, Hsu TW, Wu SR, Lan SW, et al
    Inhibition of TMPRSS2 by HAI-2 reduces prostate cancer cell invasion and metastasis.
    Oncogene. 2020 Aug 10. pii: 10.1038/s41388-020-01413.
    PubMed         Abstract available


    Oncology (Williston Park)

  17. BRODERICK JM
    Experts Develop New Guideline for Advanced Prostate Cancer.
    Oncology (Williston Park). 2020;34:305-306.
    PubMed         Abstract available

  18. CARRIL-AJURIA L, Remolina-Bonilla YA, Carretero-Gonzalez A, Martin-Soberon M, et al
    Challenges of Treating a Patient With Advanced Prostate Cancer During the COVID-19 Pandemic.
    Oncology (Williston Park). 2020;34:317-319.
    PubMed         Abstract available


    PLoS One

  19. ERB HHH, Bodenbender J, Handle F, Diehl T, et al
    Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer.
    PLoS One. 2020;15:e0237248.
    PubMed         Abstract available

  20. LYNCH SM, Handorf E, Sorice KA, Blackman E, et al
    The effect of neighborhood social environment on prostate cancer development in black and white men at high risk for prostate cancer.
    PLoS One. 2020;15:e0237332.
    PubMed         Abstract available

  21. DAOUK R, Bahmad HF, Saleh E, Monzer A, et al
    Genome-wide gene expression analysis of a murine model of prostate cancer progression: Deciphering the roles of IL-6 and p38 MAPK as potential therapeutic targets.
    PLoS One. 2020;15:e0237442.
    PubMed         Abstract available

  22. BOU-DARGHAM MJ, Sang QA
    Secretome analysis reveals upregulated granzyme B in human androgen-repressed prostate cancer cells with mesenchymal and invasive phenotype.
    PLoS One. 2020;15:e0237222.
    PubMed         Abstract available


    Prostate

  23. ELSHAFAE SM, Dirksen WP, Alasonyalilar-Demirer A, Breitbach J, et al
    Canine prostatic cancer cell line (LuMa) with osteoblastic bone metastasis.
    Prostate. 2020;80:698-714.
    PubMed         Abstract available

  24. DI BELLA CM, Howard LE, Oyekunle T, De Hoedt AM, et al
    Abdominal and pelvic adipose tissue distribution and risk of prostate cancer recurrence after radiation therapy.
    Prostate. 2020 Aug 7. doi: 10.1002/pros.24054.
    PubMed         Abstract available

  25. SHORE ND, Drake CG, Lin DW, Ryan CJ, et al
    Optimizing the management of castration-resistant prostate cancer patients: A practical guide for clinicians.
    Prostate. 2020 Aug 11. doi: 10.1002/pros.24053.
    PubMed         Abstract available

  26. PALANGMONTHIP W, Wu R, Tarima S, Bobholz SA, et al
    Corpora amylacea in benign prostatic acini are associated with concurrent, predominantly low-grade cancer.
    Prostate. 2020;80:687-697.
    PubMed         Abstract available


    Urol Int

  27. NESTLER T, Wittersheim M, Schaefer S, Hellmich M, et al
    Prediction of Radioresistant Prostate Cancer Based on Differentially Expressed Proteins.
    Urol Int. 2020 Aug 13:1-12. doi: 10.1159/000509447.
    PubMed         Abstract available

  28. FANG WY, Wang PF, Fan YC, Shih HJ, et al
    Clinical Experience of Steroid Switch from Prednisone to Dexamethasone in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate.
    Urol Int. 2020 Aug 13:1-6. doi: 10.1159/000509882.
    PubMed         Abstract available


    Urology

  29. KAHOKEHR AA, Boysen WR, Schild MH, Nose BD, et al
    Urinary pubic symphysis fistula leads to histopathologic osteomyelitis in prostate cancer survivors.
    Urology. 2020 Aug 4. pii: S0090-4295(20)30947.
    PubMed         Abstract available

  30. LAMBA N, Butler S, Mahal BA, Trinh QD, et al
    Three-tiered sub-classification system of high-risk prostate cancer in men managed with radical prostatectomy: Implications for treatment decision-making.
    Urology. 2020 Aug 4. pii: S0090-4295(20)30949.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: